ES2159552T3 - Terapia de sustitucion de hormonas. - Google Patents

Terapia de sustitucion de hormonas.

Info

Publication number
ES2159552T3
ES2159552T3 ES94909721T ES94909721T ES2159552T3 ES 2159552 T3 ES2159552 T3 ES 2159552T3 ES 94909721 T ES94909721 T ES 94909721T ES 94909721 T ES94909721 T ES 94909721T ES 2159552 T3 ES2159552 T3 ES 2159552T3
Authority
ES
Spain
Prior art keywords
substitution therapy
hormone substitution
hormone
estrogen
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94909721T
Other languages
English (en)
Inventor
Gary D Hodgen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastern Virginia Medical School
Original Assignee
Eastern Virginia Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21816657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2159552(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eastern Virginia Medical School filed Critical Eastern Virginia Medical School
Application granted granted Critical
Publication of ES2159552T3 publication Critical patent/ES2159552T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Dental Preparations (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)

Abstract

UN METODO DE TERAPIA DE SUSTITUCION DE HORMONA INCLUYE LA ADMINISTRACION DE ESTROGENO JUNTO CON UNA CANTIDAD DE ANTIPROGESTINA QUE INHIBE LA PROLIFERACION ENDOMETRIAL INDUCIDA POR ESTROGENO EN UNA MUJER.
ES94909721T 1993-02-25 1994-02-18 Terapia de sustitucion de hormonas. Expired - Lifetime ES2159552T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/023,692 US5468736A (en) 1993-02-25 1993-02-25 Hormone replacement therapy

Publications (1)

Publication Number Publication Date
ES2159552T3 true ES2159552T3 (es) 2001-10-16

Family

ID=21816657

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94909721T Expired - Lifetime ES2159552T3 (es) 1993-02-25 1994-02-18 Terapia de sustitucion de hormonas.

Country Status (25)

Country Link
US (1) US5468736A (es)
EP (1) EP0686037B1 (es)
JP (1) JP3441459B2 (es)
KR (1) KR100248857B1 (es)
AT (1) ATE202281T1 (es)
AU (1) AU680239B2 (es)
BG (1) BG62383B1 (es)
BR (1) BR9406667A (es)
CA (1) CA2157003C (es)
CZ (1) CZ290562B6 (es)
DE (1) DE69427529T2 (es)
DK (1) DK0686037T3 (es)
ES (1) ES2159552T3 (es)
FI (1) FI953926L (es)
GR (1) GR3036649T3 (es)
HU (1) HU221169B1 (es)
NO (1) NO309456B1 (es)
NZ (1) NZ262657A (es)
PL (1) PL176796B1 (es)
PT (1) PT686037E (es)
RO (1) RO115115B1 (es)
RU (1) RU2139056C1 (es)
SK (1) SK282921B6 (es)
UA (1) UA43842C2 (es)
WO (1) WO1994018983A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US6407082B1 (en) 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
AU5942700A (en) * 1996-03-11 2000-11-30 Schering Aktiengesellschaft Sequential estrogen/progestrone antagonist combination for hormone replacement theapy
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US20060014728A1 (en) * 1996-11-21 2006-01-19 Kristof Chwalisz Hormone replacement therapy
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
CA2267743C (en) * 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
RO122180B1 (ro) * 1999-08-31 2009-02-27 Jenapharm Gmbh & Co. Kg Utilizarea mezoprogestinelor în terapia de substituţie hormonală
US6432643B1 (en) * 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
NZ534348A (en) * 2000-01-28 2006-06-30 Endorech Inc Selective estrogen receptor modulators in combination with estrogens
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US8048869B2 (en) * 2001-05-18 2011-11-01 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
EP1390041B1 (en) * 2001-05-23 2009-11-25 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
DK1390042T3 (da) * 2001-05-23 2008-03-31 Pantarhei Bioscience Bv System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
CA2467222C (en) * 2001-11-15 2010-06-08 Herman Jan Tijmen Coelingh Bennink Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
DE10200405A1 (de) 2002-01-08 2002-08-01 Zimmer Ag Spinnvorrichtung und -verfahren mit Kühlbeblasung
DE10204381A1 (de) 2002-01-28 2003-08-07 Zimmer Ag Ergonomische Spinnanlage
DE10206089A1 (de) 2002-02-13 2002-08-14 Zimmer Ag Bersteinsatz
CN1691947B (zh) * 2002-06-11 2011-11-23 潘塔希生物科学股份有限公司 雌激素成分在制备用于治疗或预防免疫介导的疾病中的应用以及包含所述雌激素成分的药物组合物
US7943604B2 (en) * 2002-06-11 2011-05-17 Pantarhei Bioscience B.V. Method of treating human skin and a skin care composition for use in such a method
CA2492287C (en) * 2002-07-12 2011-12-13 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
CN100528167C (zh) * 2002-10-23 2009-08-19 潘塔希生物科学股份有限公司 用于治疗癌症的包含雌四醇衍生物的药物组合物
DK1624878T3 (da) * 2003-05-22 2007-01-08 Pantarhei Bioscience Bv Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
US9283234B2 (en) 2006-10-24 2016-03-15 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
US8236785B2 (en) * 2007-01-08 2012-08-07 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US9850273B2 (en) * 2014-12-03 2017-12-26 Evestra, Inc. Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890356A (en) * 1973-03-26 1975-06-17 Richardson Merrell Inc 7-Alkyl-{66 {hu 3,5{b -steroids
US3928398A (en) * 1973-11-01 1975-12-23 Richardson Merrell Inc Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol
US4416822A (en) * 1982-07-09 1983-11-22 The Upjohn Company 17β-Difluoromethyl steroids
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
AU572589B2 (en) * 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.

Also Published As

Publication number Publication date
JP3441459B2 (ja) 2003-09-02
HU221169B1 (en) 2002-08-28
EP0686037A4 (en) 1997-11-26
KR100248857B1 (ko) 2000-04-01
NO309456B1 (no) 2001-02-05
BR9406667A (pt) 1996-01-23
JPH08510993A (ja) 1996-11-19
NO953243L (no) 1995-08-17
BG62383B1 (bg) 1999-10-29
DE69427529T2 (de) 2001-11-22
NZ262657A (en) 1997-05-26
SK104995A3 (en) 1997-04-09
HUT72080A (en) 1996-03-28
CZ290562B6 (cs) 2002-08-14
WO1994018983A1 (en) 1994-09-01
PL310660A1 (en) 1995-12-27
AU680239B2 (en) 1997-07-24
EP0686037B1 (en) 2001-06-20
PT686037E (pt) 2001-09-28
UA43842C2 (uk) 2002-01-15
ATE202281T1 (de) 2001-07-15
CZ204895A3 (en) 1996-03-13
DK0686037T3 (da) 2001-08-27
US5468736A (en) 1995-11-21
RU2139056C1 (ru) 1999-10-10
CA2157003A1 (en) 1994-09-01
BG99880A (bg) 1996-02-28
EP0686037A1 (en) 1995-12-13
KR960700727A (ko) 1996-02-24
PL176796B1 (pl) 1999-07-30
GR3036649T3 (en) 2001-12-31
CA2157003C (en) 2001-04-17
DE69427529D1 (de) 2001-07-26
SK282921B6 (sk) 2003-01-09
HU9502306D0 (en) 1995-09-28
FI953926A0 (fi) 1995-08-22
FI953926A7 (fi) 1995-08-22
NO953243D0 (no) 1995-08-17
RO115115B1 (ro) 1999-11-30
AU6245494A (en) 1994-09-14
FI953926L (fi) 1995-08-22

Similar Documents

Publication Publication Date Title
ES2159552T3 (es) Terapia de sustitucion de hormonas.
MY113079A (en) Estrogen agonists as remedies for cardiovascular diseases
TW323953B (en) A pharmaceutical composition used to prevent or treat non-inflammatory-induced high intraocular pressure related to the application of steroids or endogenous steroids
DE69221169D1 (de) Verzweigung
NO931209D0 (no) Anordning for tarnsdermal tilfoersel av kontraseptiver
MY118392A (en) Variable day start tablet dispenser
YU48666B (sh) Mometason furoat monohidrat i postupak za njegovo dobijanje
BR9612207A (pt) Processo e kit para contracepções em mamíferos fêmeas consistindo de uma combinação de gestageno e estrogênio
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
ES2184866T3 (es) Composicion de tampon para reactivos de dosificado inmunologico.
ATE213947T1 (de) Progestogen-anti-progestogen therapien
IL141914A0 (en) Dosage form comprising liquid formulation
MX9703144A (es) Envase de seguridad frente a la accion de los niños para colocar parches portadores de principios activos.
ES2179375T3 (es) Composiciones farmaceuticas estabilizadas, a base de quinupristina y de dalfopristina y su preparacion.
EA199700449A1 (ru) Способ предотвращения остеопороза
PT1007052E (pt) Combinacoes de progestinas de crescimento do endometrico e progestinas de atropia do endometrio com estrogenios, em contracepcao oral
DE69015785D1 (de) Neutralisierbares Reduzierventil.
YU48719B (sh) Lizin so 6-hloro-5-fluoro-3-(2-tenoil)-2-oksindol-1-karboksamida
ECSP941115A (es) Composicion de fibra dietetica. metodo de preparacion y uso
MX9709426A (es) Uso de alendronato para preparar composiciones para la prevencion de la osteoporosis.
ES2141044B1 (es) Terapia con oxibutinina.
MX9707009A (es) Inyeccion de una vez al mes como un contraceptivo de base y para terapia de reemplazamiento hormonal para mujeres perimenopausicas y premenopausicas.
MX9709013A (es) Forma de dosis que comprende oxibutinina.
SK689U (sk) Obálka s doručenkou
UA10683A (uk) Засіб для лікувальhих ваhh

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 686037

Country of ref document: ES